OCUP Ocuphire Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCUP

Price (delayed)

$1.66

Market cap

$41.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

-$9.31M

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product ...

Highlights
Ocuphire Pharma's equity has increased by 8% YoY
The company's net income has shrunk by 156% YoY and by 135% QoQ
The company's EPS has shrunk by 151% YoY and by 132% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ocuphire.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of OCUP
Market
Shares outstanding
24.81M
Market cap
$41.19M
Enterprise value
-$9.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
1.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.49
Earnings
Revenue
$19.05M
EBIT
-$9.97M
EBITDA
-$9.97M
Free cash flow
-$1.11M
Per share
EPS
-$0.46
Free cash flow per share
-$0.05
Book value per share
$2.2
Revenue per share
$0.88
TBVPS
$2.5
Balance sheet
Total assets
$53.95M
Total liabilities
$4.04M
Debt
$0
Equity
$49.91M
Working capital
$49.91M
Liquidity
Debt to equity
0
Current ratio
13.35
Quick ratio
13.07
Net debt/EBITDA
5.07
Margins
EBITDA margin
-52.3%
Gross margin
100%
Net margin
-52.4%
Operating margin
-55.5%
Efficiency
Return on assets
-20.3%
Return on equity
-22.3%
Return on invested capital
-544.6%
Return on capital employed
-20%
Return on sales
-52.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCUP stock price

How has the Ocuphire Pharma stock price performed over time
Intraday
-0.6%
1 week
-9.78%
1 month
-13.09%
1 year
-73.98%
YTD
-44.85%
QTD
-17.41%

Financial performance

How have Ocuphire Pharma's revenue and profit performed over time
Revenue
$19.05M
Gross profit
$19.05M
Operating income
-$10.56M
Net income
-$9.99M
Gross margin
100%
Net margin
-52.4%
The operating income has plunged by 158% YoY and by 136% from the previous quarter
The company's net income has shrunk by 156% YoY and by 135% QoQ
The revenue has dropped by 67% since the previous quarter and by 52% year-on-year
OCUP's gross profit has shrunk by 67% QoQ and by 52% YoY

Growth

What is Ocuphire Pharma's growth rate over time

Valuation

What is Ocuphire Pharma stock price valuation
P/E
N/A
P/B
0.75
P/S
1.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.49
The company's EPS has shrunk by 151% YoY and by 132% QoQ
The P/B is 69% below the 5-year quarterly average of 2.4 and 58% below the last 4 quarters average of 1.8
Ocuphire Pharma's equity has increased by 8% YoY
The revenue has dropped by 67% since the previous quarter and by 52% year-on-year
OCUP's P/S is 10% below its last 4 quarters average of 2.1

Efficiency

How efficient is Ocuphire Pharma business performance
The ROIC has shrunk by 154% QoQ
OCUP's ROA has plunged by 134% from the previous quarter and by 129% YoY
Ocuphire Pharma's return on equity has shrunk by 134% QoQ and by 128% YoY

Dividends

What is OCUP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUP.

Financial health

How did Ocuphire Pharma financials performed over time
The total liabilities has increased by 47% year-on-year and by 3.4% since the previous quarter
The current ratio has declined by 25% year-on-year and by 3.7% since the previous quarter
Ocuphire Pharma's debt is 100% lower than its equity
Ocuphire Pharma's equity has increased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.